- Kent Lake, holding 7.7% of Quanterix (QTRX, Financial) shares, opposes the merger with Akoya Biosciences (AKYA).
- The firm describes the merger as "value-destructive" and a "bailout" for Akoya.
- Shareholders are urged to vote against the merger proposals at the May 13, 2025, special meeting.
Kent Lake, an investment firm holding approximately 7.7% of Quanterix Corporation's (QTRX) common stock, has filed a definitive proxy statement with the U.S. Securities and Exchange Commission. The firm is opposing Quanterix's proposed merger with Akoya Biosciences (AKYA), claiming the merger is "value-destructive" and characterizing it as a "bailout" for Akoya at the expense of Quanterix shareholders.
In its letter to shareholders, Kent Lake has expressed concerns over the transaction process and potential conflicts of interest among Quanterix board members. The firm has launched a campaign to rally other shareholders to vote against the merger-related proposals at the upcoming special meeting scheduled for May 13, 2025. They have set up a dedicated website, www.SaveQTRX.com, to provide voting information and resources.
Kent Lake, leveraging its 7.7% ownership stake, is actively working to gather sufficient votes to block the merger, emphasizing the need for transparency and fair valuation to protect shareholder interests. Shareholders are encouraged to cast their votes using the GOLD proxy card as instructed on the campaign website.
